West Pharmaceutical Services Net Income/Loss 2010-2025 | WST
West Pharmaceutical Services annual/quarterly net income/loss history and growth rate from 2010 to 2025. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- West Pharmaceutical Services net income/loss for the quarter ending March 31, 2025 was $0.090B, a 22.12% decline year-over-year.
- West Pharmaceutical Services net income/loss for the twelve months ending March 31, 2025 was $1.172B, a 19.76% decline year-over-year.
- West Pharmaceutical Services annual net income/loss for 2024 was $0.493B, a 16.97% decline from 2023.
- West Pharmaceutical Services annual net income/loss for 2023 was $0.593B, a 1.28% increase from 2022.
- West Pharmaceutical Services annual net income/loss for 2022 was $0.586B, a 11.47% decline from 2021.
West Pharmaceutical Services Annual Net Income/Loss
(Millions of US $) |
| 2024 |
$493 |
| 2023 |
$593 |
| 2022 |
$586 |
| 2021 |
$662 |
| 2020 |
$346 |
| 2019 |
$242 |
| 2018 |
$207 |
| 2017 |
$151 |
| 2016 |
$144 |
| 2015 |
$96 |
| 2014 |
$127 |
| 2013 |
$112 |
| 2012 |
$81 |
| 2011 |
$76 |
| 2010 |
$65 |
| 2009 |
$73 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$15.565B |
$2.893B |
|
West Pharmaceutical Services Inc. is a leading global manufacturer with respect to design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The Exton, PA-based company designs and produces these medical products in the Americas, Europe, the Middle East, Africa and the Asia Pacific. Its primary objective is to deliver quality products that cater to the exact product specifications and quality standards that customers expect and need. West Pharmaceutical operates through two segments: Proprietary Products and Contract-Manufactured Products.
|
